Involvement of miR-619-5p in resistance to cisplatin by regulating ATXN3 in oral squamous cell carcinoma.
Involvement of miR-619-5p in resistance to cisplatin by regulating ATXN3 in oral squamous cell carcinoma.
复制标题
miR-619-5p通过调节ATXN3参与口腔鳞状细胞癌顺铂耐药
DOI：
10.7150/ijbs.54014
复制
发表时间：
2021
影响因子：
9.2
通讯作者：
Song X
中科院分区：
文献类型：
--
作者：
Song A;Wu Y;Chu W;Yang X;Zhu Z;Yan E;Zhang W;Zhou J;Ding X;Liu J;Zhu H;Ye J;Wu Y;Zheng Y;Song X
MicroRNAs are major post-transcriptional regulators responsible for the development of human cancers, including OSCC. The specific role of miR-619-5p in OSCC, however, is rarely reported. Cisplatin is one of the mostly applied chemotherapy drugs of OSCC. Nevertheless, drug resistance of cisplatin following the initial chemotherapy largely restricts its clinical benefits, and the mechanism of cisplatin resistance is unclear. This study intends to explore the biological function of miR-619-5p in the development of cisplatin resistance in OSCC cell lines and a xenograft model, as well as the potential molecular mechanism. Our results showed that miR-619-5p was down-regulated in OSCC samples and cisplatin-resistant OSCC cells. Ectopically expressed miR-619-5p inhibited proliferative, migratory and invasive abilities of OSCC cisplatin-resistant cells. The putative target gene ATXN3 was predicted by bioinformatic analysis and confirmed by dual-luciferase reporter assay. Importantly, ATXN3 was responsible for the regulatory effects of miR-619-5p on biological behaviors of cisplatin-resistant OSCC cells. Moreover, miR-619-5p mimics and ATXN3-siRNA significantly enhanced ATXN3 knockdown in both HN6/CDDPR and CAL27/CDDPR cells and inhibited expression of PI3K and AKT. In vivo evidences demonstrated that intratumoral injection of miR-619-5p agomir remarkably slowed down the growth of OSCC in xenograft mice. Collectively, microRNA-619-5p was the vital regulator for regulating cisplatin resistance of OSCC, which may be served as a potential therapeutic target.
登录
查看更多内容
外泌体 microRNA-32-5p 通过 PI3K/Akt 途径诱导肝细胞癌多药耐药
DOI：
10.1186/s13046-018-0677-7
发表时间：
2018-03-12
期刊：
Journal of experimental & clinical cancer research : CR
影响因子：
--
作者：
Fu X;Liu M;Qu S;Ma J;Zhang Y;Shi T;Wen H;Yang Y;Wang S;Wang J;Nan K;Yao Y;Tian T
通讯作者：
Tian T
DOI：
10.2217/fon.12.138
发表时间：
2012-11
期刊：
Future oncology (London, England)
影响因子：
--
作者：
Gasche JA;Goel A
通讯作者：
Goel A
影响因子：
9.8
作者：
John B;Enright AJ;Aravin A;Tuschl T;Sander C;Marks DS
通讯作者：
Marks DS
miR-22/KAT6B 轴是舌鳞状细胞癌中通过调节 PI3k-Akt-NF-kB 通路的化疗决定因素
DOI：
10.1186/s13046-018-0834-z
发表时间：
2018-07-24
期刊：
Journal of experimental & clinical cancer research : CR
影响因子：
--
作者：
Gu Y;Liu H;Kong F;Ye J;Jia X;Zhang Z;Li N;Yin J;Zheng G;He Z
通讯作者：
He Z
影响因子：
5.2
作者：
Khoo, Xin-Hui;Paterson, Ian C.;Lee, Wai-Leng
通讯作者：
Lee, Wai-Leng